Baidu
map

J Abnorm Child Psych:张建新研究组揭示创伤后应激障碍临床症状结构的跨性别稳定性及其与行为问题之间的差异性关联

2017-04-27 佚名 心理研究所

在2013年公布的美国《精神障碍诊断与统计手册》第五版(简称DSM-5)中,专家组基于实证研究与临床经验对创伤后应激障碍(Posttraumatic stress disorder,PTSD)的临床症状标准进行了多项修改,由此引发了研究者们关于PTSD临床症状结构的新一轮探讨。逐渐积累起来的研究证据大多来自成人样本,它们为DSM-5界定的4维表型模型以及基于该模型修正而成的5维DSM-5精神痛苦性

在2013年公布的美国《精神障碍诊断与统计手册》第五版(简称DSM-5)中,专家组基于实证研究与临床经验对创伤后应激障碍(Posttraumatic stress disorder,PTSD)的临床症状标准进行了多项修改,由此引发了研究者们关于PTSD临床症状结构的新一轮探讨。逐渐积累起来的研究证据大多来自成人样本,它们为DSM-5界定的4维表型模型以及基于该模型修正而成的5维DSM-5精神痛苦性唤起模型、6维快感缺失模型、6维外化行为模型和7维混合模型等提供了支持。然而,目前关于青少年人群中基于DSM-5的PTSD临床症状结构的认识还相对匮乏,而上述结构是否具有跨性别的稳定性、PTSD的不同症状簇是否与青少年的行为问题具有差异性关联等问题也有待解答。

鉴于此,中国科学院心理研究所心理健康重点实验室张建新研究组及其合作者采用验证性因素分析的方法检验了1184名汶川地震幸存青少年样本中基于DSM-5的PTSD临床症状结构,结果显示由闯入、回避、负性情绪、快感缺失、外化行为、焦虑性唤起以及精神痛苦性唤起因子构成的7维混合模型对来自女性及男性的数据均具有最优的模型拟合程度;该模型在因子结构不变性、因子载荷不变性、条目截距不变性、残差方差不变性以及因子方差/协方差不变性等不同水平上均具有跨性别的稳定性;PTSD的不同症状簇与青少年的社会退缩、违纪及攻击等行为问题具有显着的差异性关联,其中社会退缩行为与PTSD的快感缺失症状的相关程度最高,而违纪及攻击行为则与PTSD的外化行为症状具有最强关联。

该研究首次考察了性别对青少年人群中基于DSM-5的PTSD临床症状结构的影响,为新近提出的7维混合模型及其跨性别稳定性提供了实证证据,同时也为针对青少年人群的PTSD临床症状的评估、诊断及性别比较提供了参考意见。此外,该研究还揭示了基于DSM-5的PTSD临床症状结构与青少年行为问题之间的差异性关联,这一方面加深了对PTSD与青少年行为功能损伤之间关系的认识,另一方面也有助于在灾害幸存青少年人群中开展针对特定PTSD临床症状的早期预防、识别及干预。

该研究受国家支撑计划项目(2013BAI08B02)、中科院重点部署项目(KJZD-EW-L04)、国家自然科学基金项目(31271099,31471004)以及中科院国际人才交流计划(2016VEA019)支持,研究成果已发表于儿童青少年心理病理学期刊Journal of Abnormal Child Psychology。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783103, encodeId=02361e8310355, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Dec 15 07:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661941, encodeId=094516619415e, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Sep 30 05:52:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900452, encodeId=cc2f190045284, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Nov 21 08:52:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910711, encodeId=c7b21910e11e2, content=<a href='/topic/show?id=0934229139c' target=_blank style='color:#2F92EE;'>#临床症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22913, encryptionId=0934229139c, topicName=临床症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Mon May 22 04:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335136, encodeId=7b631335136ad, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445149, encodeId=2fcb144514906, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783103, encodeId=02361e8310355, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Dec 15 07:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661941, encodeId=094516619415e, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Sep 30 05:52:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900452, encodeId=cc2f190045284, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Nov 21 08:52:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910711, encodeId=c7b21910e11e2, content=<a href='/topic/show?id=0934229139c' target=_blank style='color:#2F92EE;'>#临床症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22913, encryptionId=0934229139c, topicName=临床症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Mon May 22 04:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335136, encodeId=7b631335136ad, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445149, encodeId=2fcb144514906, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-09-30 docwu2019
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783103, encodeId=02361e8310355, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Dec 15 07:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661941, encodeId=094516619415e, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Sep 30 05:52:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900452, encodeId=cc2f190045284, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Nov 21 08:52:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910711, encodeId=c7b21910e11e2, content=<a href='/topic/show?id=0934229139c' target=_blank style='color:#2F92EE;'>#临床症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22913, encryptionId=0934229139c, topicName=临床症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Mon May 22 04:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335136, encodeId=7b631335136ad, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445149, encodeId=2fcb144514906, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783103, encodeId=02361e8310355, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Dec 15 07:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661941, encodeId=094516619415e, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Sep 30 05:52:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900452, encodeId=cc2f190045284, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Nov 21 08:52:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910711, encodeId=c7b21910e11e2, content=<a href='/topic/show?id=0934229139c' target=_blank style='color:#2F92EE;'>#临床症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22913, encryptionId=0934229139c, topicName=临床症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Mon May 22 04:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335136, encodeId=7b631335136ad, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445149, encodeId=2fcb144514906, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1783103, encodeId=02361e8310355, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Dec 15 07:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661941, encodeId=094516619415e, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Sep 30 05:52:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900452, encodeId=cc2f190045284, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Nov 21 08:52:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910711, encodeId=c7b21910e11e2, content=<a href='/topic/show?id=0934229139c' target=_blank style='color:#2F92EE;'>#临床症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22913, encryptionId=0934229139c, topicName=临床症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Mon May 22 04:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335136, encodeId=7b631335136ad, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445149, encodeId=2fcb144514906, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1783103, encodeId=02361e8310355, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Dec 15 07:52:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661941, encodeId=094516619415e, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Sep 30 05:52:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900452, encodeId=cc2f190045284, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Nov 21 08:52:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910711, encodeId=c7b21910e11e2, content=<a href='/topic/show?id=0934229139c' target=_blank style='color:#2F92EE;'>#临床症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22913, encryptionId=0934229139c, topicName=临床症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3860283, createdName=whmdzju, createdTime=Mon May 22 04:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335136, encodeId=7b631335136ad, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445149, encodeId=2fcb144514906, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Apr 29 06:52:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]

相关资讯

CHEST:OSA综合征严重影响创伤后应激障碍患者的症状和生活质量

研究人员试图确定OSA综合征(OSAS)对于创伤后应激障碍(PTSD)患者的症状和生活质量(QOL)的影响。此外,研究人员还评估了在该人群中气道正压(PAP)的治疗的依从性和响应。这是在学术军事医疗中心的睡眠障碍中心进行的病例对照观察性队列研究。200例连续PTSD患者接受睡眠评估。研究人员对患有PTSD并有和没有OSAS的患者与50名连续年龄匹配的患友OSAS但无PTSD患者和50名年龄匹配的正

JAMA:正念减压治疗能否帮助创伤后应激障碍患者走出阴影?

正念减压(MBSR)由美国麻省大学医学中心的Jon  Kabatzinn博士所创立,用于辅助(而非取代)一般的医疗行为,参与疗程的病患通常各自患有不同的生理或心理疾病,MBSR旨在教导病患运用自己内在的身心力量,为自己的身心健康积极地做一些他人无法替代的事——培育正念。对于存在创伤后应激障碍(PTSD)的退伍军人来说,其对现存循证治疗的依从性较差,以正念为基础的干预措施也许更易被其接受。

Psychological Sci:新奇!俄罗斯方块竟能治疗创伤后应激障碍!

速来围观!俄罗斯方块竟能有效治疗创伤后应激障碍! 对于患有创伤后应激障碍的患者,不必要的回忆是其常见症状的表现。但是最新的一项研究表明,创伤发生24小时后玩玩电脑游戏可以减小这种症状的发生。据估计,每年大约7-8%的美国人可因在生活中经历创伤,而后产生应激障碍(PTSD),而女性比男性更易发展为PTSD。PTSD是由于个体暴露于巨大创伤事件中引起的,其症状包括精神紧张、睡眠障碍、

BMJ Open:创伤后应激障碍与心血管疾病事件相关

目的:创伤后应激障碍(PTSD)是心血管疾病(CVD)的危险因素。然而,另一种常见的应激障碍调节障碍与心血管疾病的风险增加是否相关,以及这种相关是否存在性别差异。本研究的目的是调查创伤后应激障碍和及调节障碍和4个心血管事件之间的整体和性别分层的相关性。设计:利用丹麦国家注册数据的一项前瞻性队列研究。设置:丹麦总人口。参与者:1995到2011年间,创伤后应激障碍(n = 4724)和调节障碍(N

BMJ Open:厉害了,word太极!可有效治疗创伤后应激障碍

创伤后应激障碍(PTSD)是一种心理健康疾病,通常发生在经历或目睹一个令人震惊或可怕的事件之后。约7-8%的美国人会经历PTSD,以退伍军人尤甚,约23%的退伍军人受PTSD的困扰。PTSD的治疗通常包括药物和行为疗法,然而,这些治疗并不总是有效的。近日,来自马萨诸塞州波士顿大学医学院的一项新的研究表明,中国的一种古老的运动-太极,可有效帮助退伍军人管理其PTSD的症状,其研究结果已发表于BMJ

Molecular Psychiatry:常用抗生素可能有助于预防或治疗创伤后应激障碍

根据UCL和苏黎世大学的新研究,常见的抗生素多西环素可以破坏大脑中负面记忆的形成。

Baidu
map
Baidu
map
Baidu
map